Jiangsu Hengrui Medicine co Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (30)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Jiangsu Hengrui Medicine Co. - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Jiangsu Hengrui Medicine Co. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in phase-I. There is 1 cancer drug by Jiangsu Hengrui Medicine Co. which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Jiangsu Hengrui Medicine Co. - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Jiangsu Hengrui Medicine Co. - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Jiangsu Hengrui Medicine Co. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “13” cancer drugs in clinical pipeline and majority of them are in phase-I. There is 1 cancer drug by Jiangsu Hengrui Medicine Co. which is commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Jiangsu Hengrui Medicine Co. - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Jiangsu Hengrui Medicine Co.

  1.1 Business Overview

  1.2 Jiangsu Hengrui Medicine co Cancer Pipeline Overview

 

2. Jiangsu Hengrui Medicine Co. Cancer Drugs in Research Phase

  2.1 Immuno-Oncology Therapeutics- Jiangsu Hengrui Medicine/ University of Texas MD Anderson Cancer Center

  2.2 Cancer Therapeutics - Albert Einstein College of Medicine/Jiangsu Hengrui Medicine

 

3. Jiangsu Hengrui Medicine Co. Cancer Drugs in Preclinical Phase

  3.1 Cancer Therapeutics - Eternity Bioscience

 

4. Jiangsu Hengrui Medicine Co. Cancer Drugs in Phase-I

  4.1 INCSHR 1210

  4.2 HS 10241

  4.3 SHR 3162

  4.4 SHR 6390

  4.5 EBI 215

  4.6 Fluzoparib

 

5. Jiangsu Hengrui Medicine Co. Cancer Drugs in Phase-I/II

  5.1 SHR 3680

 

6. Jiangsu Hengrui Medicine Co. Cancer Drugs in Phase-II

  6.1 Pyrotinib

 

7. Jiangsu Hengrui Medicine Co. Cancer Drugs in Phase-III

  7.1 Famitinib

  7.2 Flumatinib

 

8. Jiangsu Hengrui Medicine Co. Cancer Drugs in Marketed

  8.1 Apatinib

 

9. No Development Reported in Cancer Drugs in Clinical Pipeline

  9.1 Henatinib


Figure 1-1: Jiangsu Hengrui Medicine Co. Cancer Pipeline by Phase (%)

Figure 1-2: Jiangsu Hengrui Medicine Co Cancer Pipeline by Phase (Number)